Alpelisib and Pioglitazone and Glimepiride Tablets
Determining the interaction of Alpelisib and Pioglitazone and Glimepiride Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9. MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered. References "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9.
MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered.
- "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: glimepiride / pioglitazone
Brand name: Duetact
Synonyms: Glimepiride and pioglitazone, Pioglitazone and Glimepiride
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alpelisib-Pioglitazone and metformin
- Alpelisib-Pioglitazone and Metformin Extended-Release Tablets
- Alpelisib-Pioglitazone and Metformin Tablets
- Alpelisib-Pioglitazone Hydrochloride
- Alpelisib-Pioglitazone Tablets
- Alpelisib-Piperacillin
- Pioglitazone and Glimepiride Tablets-Alph-E
- Pioglitazone and Glimepiride Tablets-Alph-E-Mixed
- Pioglitazone and Glimepiride Tablets-Alph-E-Mixed 1000
- Pioglitazone and Glimepiride Tablets-Alpha Lipoic Acid
- Pioglitazone and Glimepiride Tablets-Alpha-E
- Pioglitazone and Glimepiride Tablets-Alphagan P